Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells.

导出 LinkOut

翻译打印收藏纠错

第一作者： Qiang,Wang

第一单位： Department of Molecular Cell Biology and Toxicology, Key Laboratory of Modern Toxicology of the Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China.

作者： Qiang,Wang ^[1] ; Jianping,Xiong ^[1] ; Danping,Qiu ^[1] ; Xue,Zhao ^[1] ; Donglin,Yan ^[1] ; Wenxia,Xu ^[2] ; Zhangding,Wang ^[1] ; Qi,Chen ^[1] ; Sapna,Panday ^[1] ; Aiping,Li ^[1] ; Shouyu,Wang ^[3] ; Jianwei,Zhou ^[4]

作者单位： Department of Molecular Cell Biology and Toxicology, Key Laboratory of Modern Toxicology of the Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China. ^[1] Laboratory of Cancer Biology, Biomedical Research Center, Sir Runrun Shaw Hospital, Zhejiang University, Hangzhou, China. ^[2] Department of Molecular Cell Biology and Toxicology, Key Laboratory of Modern Toxicology of the Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China. Electronic address: sywang@njmu.edu.cn. ^[3] Department of Molecular Cell Biology and Toxicology, Key Laboratory of Modern Toxicology of the Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, China. Electronic address: jwzhou@njmu.edu.cn. ^[4]

关键词 Cisplatin Drug resistance Gastric cancer NHEJ pathway PARP1